Trametinib was proposed for each case after discussion in the molecular tumor board based on preclinical rationale, suggesting that MEK inhibition can be effective in NF1-deficient tumors (14, 15), and by extrapolation from evidence in other NF1-altered cancers (6). This evidence concerns the gene MAP2K7 and cancer.